CIC
NRIX icon

Cornercap Investment Counsel’s Nurix Therapeutics NRIX Stock Holding History

Cornercap Investment Counsel’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-18,358
Closed -$383K – 610
2024
Q2 		$383K Sell
18,358
-153
-0.8% -$2.38K 0.06% 509
2024
Q1 		$272K Hold
18,511
– – 0.04% 525
2023
Q4 		$191K Hold
18,511
– – 0.03% 535
2023
Q3 		$145K Sell
18,511
-245
-1% -$2.24K 0.03% 516
2023
Q2 		$187K Hold
18,756
– – 0.03% 520
2023
Q1 		$167K Hold
18,756
– – 0.03% 515
2022
Q4 		$206K Buy
+18,756
New +$226K 0.04% 515

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Cornercap Investment Counsel's NRIX Position: Q3 2024 in Review

Cornercap Investment Counsel sold out of Nurix Therapeutics (NRIX) in Q3 2024, closing a stake of 18,358 shares — an estimated $383K sold.

Cornercap Investment Counsel first reported a position in NRIX in Q4 2022 and held it in 7 quarters. The position peaked at $383K in Q2 2024. 172 funds tracked by Wall St. Rank hold NRIX as of Q3 2024.

  • Cornercap Investment Counsel reported no remaining Nurix Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Cornercap Investment Counsel sold 18,358 Nurix Therapeutics shares in Q3 2024, an estimated $383K.
  • Cornercap Investment Counsel first reported a position in Nurix Therapeutics in Q4 2022 and held it in 7 quarters.
  • Cornercap Investment Counsel's Nurix Therapeutics position peaked at $383K in Q2 2024.
  • 172 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2024.

Based on Cornercap Investment Counsel's 13F filing for Q3 2024, filed 6 Nov 2024.